Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Operating Income: 2012-2025

Historic Operating Income for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Sep 2025 value amounting to -$18.4 million.

  • Enanta Pharmaceuticals' Operating Income rose 38.41% to -$18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$85.3 million, marking a year-over-year increase of 29.86%. This contributed to the annual value of -$85.3 million for FY2025, which is 29.86% up from last year.
  • As of Q3 2025, Enanta Pharmaceuticals' Operating Income stood at -$18.4 million, which was up 2.68% from -$18.9 million recorded in Q2 2025.
  • In the past 5 years, Enanta Pharmaceuticals' Operating Income registered a high of -$18.4 million during Q3 2025, and its lowest value of -$39.5 million during Q1 2023.
  • For the 3-year period, Enanta Pharmaceuticals' Operating Income averaged around -$28.6 million, with its median value being -$29.9 million (2024).
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Operating Income slumped by 150.11% in 2021, and later spiked by 38.41% in 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Operating Income (Quarterly) stood at -$30.4 million in 2021, then grew by 1.30% to -$30.0 million in 2022, then decreased by 16.24% to -$34.9 million in 2023, then spiked by 32.51% to -$23.5 million in 2024, then surged by 38.41% to -$18.4 million in 2025.
  • Its Operating Income was -$18.4 million in Q3 2025, compared to -$18.9 million in Q2 2025 and -$24.5 million in Q1 2025.